MedTrace Logo

An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients

NCT02118597 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2016-12-12

Study results available
· View outcomes & findings →

Summary

This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with genotype 1 chronic hepatitis C (CHC) infection. Dosing and treatment duration were at the discretion of the investigator in accordance with local clinical practice and local labeling. Participants were to be observed for the duration of their triple combination therapy and for up to 24 weeks thereafter.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Boceprevir

Boceprevir administered according to corresponding summary of product characteristics (SmPC).

DRUG

Simeprevir

Simeprevir administered according to corresponding summary of product characteristics (SmPC).

DRUG

Pegylated Interferon (Peginterferon) Alfa-2a

Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).

DRUG

Ribavirin

Ribavirin according to corresponding summary of product characteristics (SmPC).

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02118597 on ClinicalTrials.gov